RESEARCH PROPOSAL ON THEY SURVIVAL ANALYSIS OF BREATH CANCER.pptx

THIS PRESENTATION IS ON THE RESEARCH PROPOSAL ABOUT BREAST CANCER

1. SURVIVAL ANALYSIS OF HER-2 LOW EARLY BREAST CANCER AT A TERTIARY GOVERNMENT HOSPITAL IN ZAMBOANG CITY, PHILIPPINES TEMIE PAUL B. VILLARINO, MD Department of Internal Medicine Zamboanga City Medical Center Primary Investigator NELSON A. LAJA, MD Adviser

2. INTRODUCTION Breast cancer remains one of the most prevalent malignancies among women worldwide, including in the Philippines. Advances in molecular profiling have led to the classification of breast cancer into subtypes based on hormone receptor status and the expression of the human epidermal growth factor receptor 2 (HER2). These subtypes have significant implications for prognosis and treatment strategies. While HER2-positive breast cancer has been well-studied due to its targeted therapies , less is known about HER2 receptor-negative and HER2 receptor-low breast cancer , which may represent a unique clinical and biological entity

3. SIGNIFICANCE The study is highly relevant for both clinical practice and public health, especially in resource-limited settings like Zamboanga City Medical Center. Improved Understanding of HER-2 Subtypes Localized Data Addressing Gaps in Research

4. GENERAL Objective This study aims to determine the disease-free survival (DFS) and Overall Survival (OS) rates of HER-2 LOW EARLY BREAST CANCER.

5. SPECIFIC Objectives 1. Analyze the OS AND DFS of HER-2 LOW EARLY BREAST CANCER PATIENTS COMPARED TO HER-2 NEGATIVE AND HER-2 POSITIVE BREAST CANCER PATIENTS. 11. DETERMINE THE DEMOGRAPHIC PROFILE OF HER-2 LOW EARLY BREAST CANCER PATIENTS. 111. Determine the relation of other variables such as age and menopausal status in the prognosis of HER-2 low EARLY breast cancer patients.

6. Research methodology Design : retrospective cohort SAMPLING TECHNIQUE PURPOSIVE SAMPLING

7. Research methodology inclusion criteria ALL PATIENTS HISTOLOGICALLY DIAGNOSED WITH BREAST CANCER FROM JANUARY 2022 TO DECEMBER 2024 ALL PATIENTS WITH AVAILABLE MOLECULAR PROFILE IMMUNOSTAINING/FISH RESULTS OF HER-2 NEU. ALL PATIENTS MUST HAVE UNDERGONE THE RECOMMENDED ADJUVANT TREATMENT.

8. Research methodology exclusion criteria 1. Incomplete Data: Patients with missing or incomplete medical records, particularly HER-2 status or survival outcomes. 2. Other Malignancies: Patients with concurrent or prior malignancies other than breast cancer that could confound survival outcomes. 3. Lost to Follow-Up: Patients who were lost to follow-up with no survival status or treatment outcome recorded. 4. REFUSED Treatment Cases: Patients who declined treatment or did not receive any form of management at the hospital.

9. Research methodology SAMPLE SIZE 132

10. Research methodology DATA COLLECTION Data will be collected from patient medical records, including demographics, clinical characteristics, treatment regimens, and follow-up outcomes. Variables of interest include age, tumor stage, hormone receptor status, treatment type, and survival time.

11. Research methodology DATA ANALYSIS Survival analysis techniques, such as Kaplan-Meier curves , will estimate survival probabilities, and the log-rank test will compare survival curves between groups. Cox proportional hazards regression will identify prognostic factors associated with survival outcomes.

12. Table 1. Demographic and clinical characteristics of HER-2 negative, low, and positive breast cancer patients.

13. Figure 1. Kaplan-Meier Survival Curve for Disease-Free Survival (DFS)

14. Figure 2. Kaplan-Meier Survival Curve for Overall Survival (OS)

15. Table 3. Hazard Ratios from Cox Proportional Hazards Regression for Prognostic Factors

16. Figure 3. Comparison of Survival Rates for HER-2 Negative, HER-2 Low, and HER-2 Positive Breast Cancer Patients

17. THANK YOU!